A medical hashish facility is headed for Kent, due to a report $100m funding by GW Prescribed drugs.
The brand new proprietor of the British pharma agency, Jazz Prescribed drugs, will construct manufacturing facility at its current website at Kent Science Park in Sittingbourne, The Occasions first reported.
Following the $7.2bn takeover, greater than 100 new, “extremely expert” jobs are anticipated to open in 2024.
The funding is “far and away the biggest capital funding within the organisation’s historical past,” in response to Jazz Prescribed drugs’ head of Europe and worldwide, Chris Tovey.
GW, which commercially grows hashish at secret places throughout the nation, kinds a part of a rising wave of pharmaceutical corporations seeking to capitalise on shifting attitudes in direction of the drug.
The Kent facility, beforehand owned by vitality big Shell, has fallen underneath GW’s wing because it was based in 1998.
The location’s growth is predicted to spice up the group’s revenues from $3bn to $5bn in 2025.
Science minister George Freeman stated the funding was a “large signal of confidence within the UK life science ecosystem”, which the nation has been seeking to strengthen post-Brexit.
Freeman added that it additionally indicators confidence in “UK experience in cannabinoid science and medicines”.
